ABC | Volume 112, Nº5, May 2019

Brief Communication Hastenteufel et al Continuous intravenous inotropes in ward units Arq Bras Cardiol. 2019; 112(5):573-576 1. Mebazaa A, Motiejunaite J, Gayat E, Crespo-LeiroMG, Lund LH, Maggioni AP, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(2):332-41. 2. GuglinM,KaufmanM. Inotropesdonot increasemortality inadvancedheart failure. Int J Gen Med. 2014;7:237-51. 3. R: A language and environment for statistical computing: Reference Index –[Internet]. [Cited in 2017 Jan 12]. Available from: softlibre.unizar.es/ manuales/aplicaciones/fullrefman.pdf 4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-52. 5. Pinney SP, Stevenson LW. Chronic inotropic therapy in the current era: old wines with new airings. Circ Heart Fail. 2015;8:843-6. References This is an open-access article distributed under the terms of the Creative Commons Attribution License Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 576